Alopecia

ORLANDO — Bempikibart demonstrated positive, durable responses among patients with severe to very severe alopecia areata, according to a late-breaking presentation at the American Academy of Dermatology Annual Meeting.

ORLANDO — Outgoing American Academy of Dermatology President Seemal R. Desai, MD, FAAD, passed the torch to Susan C. Taylor, MD, FAAD, who said she will continue pushing efforts to unify the organization during “a time of great disruption.”

ORLANDO — Oral ivarmacitinib, administered 4 mg or 8 mg once daily, significantly induced hair regrowth at 24 weeks vs. placebo in adults with severe alopecia areata, according to phase 3 data presented here.

ORLANDO — Thirty-six weeks of once-daily, oral baricitinib was associated with greater hair regrowth on the scalp, eyebrows and eyelashes compared with placebo in adolescents with severe alopecia areata, data show.

Healio Dermatology will be reporting live at South Beach Symposium 2025 from Feb. 6 to 8 in Miami Beach, Florida. The 23rd annual event will deliver the latest updates in medical and aesthetic dermatology from top experts in the field.

The Wall Street Journal has published an article labeling dermatology as the “it” job in medicine due to seemingly glamorous perks, prompting a defense from the American Academy of Dermatology.

One in eight women will suffer from breast cancer in their lifetime. Eight percent will decline treatment due to the fear of alopecia.

Major strides have been made in alopecia research in 2024. The FDA’s approval of the oral Janus kinase inhibitor Leqselvi was the most-read alopecia article on Healio this year, with studies about minoxidil and metformin also making the list.

A combination of topical finasteride and minoxidil was more efficacious than minoxidil alone in the treatment of male pattern androgenic alopecia, according to a study.

Beneath the Surface is a video series in which Joel M. Gelfand, MD, MSCE, Healio cDermatology Chief Medical Editor, discusses hot topics in the field with leading experts.